Plasmablastic Lymphoma — Trials

Plasmablastic Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 12
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 8%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04915248	Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.(FIL_DALYA)	recruiting	Phase 2	28	Fondazione Italiana Linfomi - ETSOTHER	1	Sep 9, 2026	clinicaltrials
NCT07647432	HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV(HEME-25)	not yet recruiting	Phase 2 / Phase 3	17	University of Illinois at ChicagoOTHER